Personalis Retained Earnings (Accumulated Deficit) 2018-2024 | PSNL
Personalis retained earnings (accumulated deficit) from 2018 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Personalis Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2023 |
$-469 |
| 2022 |
$-360 |
| 2021 |
$-247 |
| 2020 |
$-182 |
| 2019 |
$-141 |
| 2018 |
$-116 |
| 2017 |
$ |
Personalis Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024-06-30 |
$-494 |
| 2024-03-31 |
$-482 |
| 2023-12-31 |
$-469 |
| 2023-09-30 |
$-442 |
| 2023-06-30 |
$-413 |
| 2023-03-31 |
$-389 |
| 2022-12-31 |
$-360 |
| 2022-09-30 |
$-329 |
| 2022-06-30 |
$-303 |
| 2022-03-31 |
$-275 |
| 2021-12-31 |
$-247 |
| 2021-09-30 |
$-227 |
| 2021-06-30 |
$-209 |
| 2021-03-31 |
$-194 |
| 2020-12-31 |
$-182 |
| 2020-09-30 |
$-169 |
| 2020-06-30 |
$-159 |
| 2020-03-31 |
$-150 |
| 2019-12-31 |
$-141 |
| 2019-09-30 |
$-134 |
| 2019-06-30 |
$-127 |
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2018-06-30 |
|
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.278B |
$0.073B |
|
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
|
